Report: AstraZeneca ‘cherry-picked’ data in its U.S. COVID vaccine trial

Report: AstraZeneca ‘cherry-picked’ data in its U.S. COVID vaccine trial
Pixabay

[Ed. – More ‘science.’]

AstraZeneca may have used “outdated information” when it released data from a late-stage trial of its COVID-19 vaccine early Monday, federal officials say. The Data and Safety Monitoring Board (DSMB) said late in the day it “was concerned” about the information the British drug maker made public about the large-scale U.S. trial of the vaccine it developed along with Oxford University.

The National Institute of Allergy and Infectious Diseases (NIAID) said “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study. …

Trending: Biden: ‘No amendment to the Constitution is absolute.’ Got your amendments right here, Mr. President

Continue reading →

Comments

For your convenience, you may leave commments below using Disqus. If Disqus is not appearing for you, please disable AdBlock to leave a comment.